Stifel lowered the firm’s price target on Staar Surgical (STAA) to $18 from $19 and keeps a Hold rating on the shares. Q4 results were “somewhat noisy,” says the analyst. While the firm is not sure investors will see through the limited near-term visibility, it “may not push back against longer-term investors walking away from earnings feeling somewhat better,” the analyst added.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on STAA:
- Staar Surgical: Short-Term Revenue Headwinds and 2026 Recovery Hopes Support Neutral Hold Rating
- Staar Surgical: Uncertain China Outlook and Post‑Alcon Fallout Justify Maintaining Hold Rating
- Closing Bell Movers: GitLab down 9% on earnings, AI threat
- Staar Surgical Reports Q4 2025 Results and Outlook
- Staar Surgical reports Q4 EPS 0c, consensus 17c